Loxo Oncology has earned considerable buzz and a hefty stock market valuation for bringing a genomic-based approach to cancer drug development. The Connecticut biotech’s drugs target highly specific genetic mutations found in cancer cells, regardless of where in the body the tumor is located.

The first of Loxo’s experimental drugs, larotrectinib, has already demonstrated a strong cancer-killing ability in tumors with a genetic alteration called a TRK gene fusion. The drug is under FDA review with an approval decision expected in late November.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy